GC녹십자는 코로나19 혈장치료제로 개발 중인 'GC5131A'를 국내 환자들에게 수량 제한 없이 무상 제공하겠다고 밝혔다.
GC Green Cross announced that it would provide "GC5131A", which is being developed as a blood treatment for COVID-19, free of charge to patients in Korea without limitation in quantity.